- Home
- NUW vs GOSS Comparison
NUW vs GOSS Comparison
Compare NUW & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | GOSS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.0M | 101.2M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NUW | GOSS |
|---|---|---|
| Price | $13.89 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 30.0K | ★ 14.1M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.04 | $0.32 |
| 52 Week High | $14.62 | $3.87 |
Technical Indicators
Market Signals| Indicator | NUW | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 25.79 | 24.12 |
| Support Level | $13.51 | $0.33 |
| Resistance Level | $14.51 | $0.60 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 9.10 | 14.09 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.